Article
The deals
The Franklin, Tenn.-based operator expects the nine sales to bring in more than $1.2 billion in 2026. Three Pennsylvania hospitals in the Scranton and Wilkes-Barre area went to the nonprofit Tenor Health Foundation on Feb. 1, after an earlier sale to another buyer fell apart in 2024. Freeman Health System of Joplin, Mo., agreed to pay $112 million for four Northwest Arkansas hospitals, a deal that would double Freeman’s hospital count and take CHS out of Arkansas. Huntsville Hospital Health System agreed to buy Crestwood Medical Center for $450 million, and Vanderbilt University Medical Center plans to pay $600 million for CHS’s 80% stake in the joint ventures that own Tennova Healthcare-Clarksville. The Arkansas and Alabama sales are expected to close in the second quarter, pending approvals.
For CHS, the strategy is about debt and focus. The company has sold roughly 35% of its hospitals in recent years, has cut debt by more than $3 billion since 2019, and now owns or leases 65 hospitals in 13 states. Its CEO has said many divested hospitals did not fit its network-of-care strategy.
Why the buyer side matters
Nearly every buyer here is a nearby nonprofit or academic system extending its regional footprint rather than a national chain. For those organizations, a divested hospital can fill a geographic gap, add referral volume and keep a competitor from moving in. It can also bring service lines that need investment, payer contracts priced for a different owner and a medical staff unsure about the new parent. The Pennsylvania history shows that a signed deal is not a closed one when the buyer’s financing is uncertain.
Price is only part of the cost. Information systems conversion, deferred maintenance, recruitment and the work of combining two cultures can exceed the purchase price over several years, and those costs land while the buyer’s own margin is under pressure.
Questions boards should ask
- Strategic fit: Does the hospital strengthen a network we already run, or does it create a new market we must build from scratch?
- Total cost: What will the first five years of capital, systems conversion and recruitment cost, and how does that compare with the purchase price?
- Payer reset: Can existing commercial contracts be moved to our terms, and how long will that take?
- Regulatory path: How will state reviewers and federal antitrust staff view the combination, and what commitments might they require?
- Community promises: Which services are we prepared to guarantee, and for how long?
Archive entry for Mar 23, 2026, added Nov. 11, 2026.